Astellas Inks $1.54 Billion Licensing Deal with Evopoint for ADC Candidate XNW27011 Targeting CLDN18.2

- Agreement grants Astellas exclusive worldwide rights (excluding China's mainland, Hong Kong, Macao and Taiwan region) to develop and commercialize XNW2...

May 30, 2025 | Friday | News
Candel Therapeutics Secures FDA RMAT Designation for CAN-2409 in Localized Prostate Cancer

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological ...

May 29, 2025 | Thursday | News
GlycoEra Secures $130M Series B to Advance First-in-Class IgG4 Protein Degrader Into Clinical Trials

Financing led by Novo Holdings with significant support from world-class group of existing and new investors Proceeds from financing to support developm...

May 28, 2025 | Wednesday | News
Roche’s Itovebi™ Receives Positive CHMP Opinion for First-Line Treatment of PIK3CA-Mutated Advanced Breast Cancer

Positive recommendation based on phase III INAVO120 data showing ItovebiTM (inavolisib) in combination with palbociclib and fulvestrant more than doubl...

May 26, 2025 | Monday | News
QIAGEN and ID Solutions Partner to Expand Oncology dPCR Assay Portfolio on QIAcuity Platform

Partnership designed to expand QIAGEN’s leadership in oncology-focused digital PCR assays, advancing QIAcuity as the platform of choice for can...

May 23, 2025 | Friday | News
Astellas and Pfizer’s XTANDI Demonstrates 30% Reduced Risk of Death at Five Years in mHSPC Patients

Astellas Pharma Inc. (TSE: 4503) and Pfizer Inc. (NYSE: PFE)  announced compelling five-year overall survival (OS) results from the open-label exten...

May 23, 2025 | Friday | News
Xuanzhu Biopharma’s Bireociclib Approved by NMPA Marks Breakthrough in Advanced Breast Cancer Treatment in China

National Medical Products Administration attracted widespread attention in the oncology community and the pharmaceutical market. Bireociclib tablets (tra...

May 16, 2025 | Friday | News
Invenra Launches T-Body™ Trispecific Antibody Platform to Advance Next-Gen Multispecific Therapeutics

Invenra Inc., a pioneer in multispecific antibody discovery and development, announces the launch of its T-Body™ trispecific antibody platform, a n...

May 14, 2025 | Wednesday | News
Exelixis Advances Invenra-Discovered XB628 into Phase 1 Clinical Trial for Solid Tumors

Invenra Inc., a biotechnology company specializing in the discovery and development of multispecific antibodies,  announced that its collaboration par...

May 14, 2025 | Wednesday | News
Hovione and Firstgene Partner to Advance Precision Gene Therapy for Liver Cancer Using Novel AAV-Like Vector Platform

Exclusive licensing and R&D collaboration accelerate the development of a novel gene vector platform for precision gene therapy in Hepatocellular Car...

May 07, 2025 | Wednesday | News
“Too Quiet to Fund?” Jude Research Reveals Bladder Cancer Is One of the UK's Most Underfunded Major Cancers

  To mark Bladder Cancer Awareness Month this May, bladder health brand Jude has conducted new research into how much charitable funding is allocat...

May 06, 2025 | Tuesday | Reports
Australia’s Immutep Achieves 17.6-Month Survival with Chemo-Free Immunotherapy in Head and Neck Cancer

Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer patients with PD-L1 CPS...

May 06, 2025 | Tuesday | News
Can-Fite Secures $175M to Advance Oral A3AR Therapies into Phase III for Liver Cancer and Psoriasis

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory diseases, toda...

May 06, 2025 | Tuesday | News
Crown Bioscience Extends Exclusive Partnership with NEXT Oncology to Advance Translational Cancer Research

Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corp...

May 02, 2025 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close